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Abstract
Background: Trial participants in placebo groups report experiencing adverse events (AEs). Existing systematic
reviews have not been synthesized, leaving questions about why these events occur as well as their prevalence
across different conditions unanswered.
Objectives:
(1) To synthesize the evidence of prevalence of AEs in trial placebo groups across different conditions.
(2) To compare AEs in trial placebo groups with AEs reported in untreated groups within a subset of randomized
trials.
Search methods: We searched PubMed for records with the word “nocebo” in the title and “systematic” in any
field. We also contacted experts and hand-searched references of included studies.
Study eligibility: We included any systematic review of randomized trials where nocebo effects were reported. We
excluded systematic reviews of non-randomized studies.
Participants and interventions: We included studies in any disease area.
Study appraisal and synthesis methods: We appraised the quality of the studies using a shortened version of the
Assessment of Multiple Systematic Reviews tool (AMSTAR) tool. We reported medians and interquartile ranges
(IQRs) of AEs. Among the trials within the review that included untreated groups, we compared the prevalence of
AEs in untreated groups with the prevalence of AEs in placebo groups.
Results: We identified 20 systematic reviews. These included 1271 randomized trials and 250,726 placebo-treated
patients. The median prevalence of AEs in trial placebo groups was 49.1% (IQR 25.7–64.4%). The median rate of
dropouts due to AEs was 5% (IQR 2.28–8.4%). Within the 15 of trials that reported AEs in untreated groups, we
found that the AE rate in placebo groups (6.51%) was higher than that reported in untreated groups (4.25%).
Limitations: This study was limited by the quality of included reviews and the small number of trials that included
untreated groups.
Conclusions and implications of key findings: AEs in trial placebo groups are common and cannot be attributed
entirely to natural history. Trial methodologies that reduce AEs in placebo groups while satisfying the requirement
of informed consent should be developed and implemented.
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Background
Some recent systematic reviews suggest that trial par-
ticipants who are allocated to placebo groups experi-
ence adverse events (AE), including AEs attributed to
apparent drug interactions [1–6]. Yet adverse drug re-
actions cannot be directly caused by placebo treat-
ments. There are two overlapping explanations for how
this might occur. First, a patient may have an under-
lying condition whose natural history produces some
event (such as a headache), then the patient misattrib-
utes the event to the trial intervention (in their case,
a placebo). Second, having been warned about side ef-
fects in the patient information sheets (or elsewhere),
the patient may expect an AE. This negative expect-
ation could then produce the event [7]. There is some
empirical support for the latter explanation. In one
multicenter randomized trial of aspirin or sulfinpyra-
zone for treating unstable angina, due to differences in
individual hospital review processes, patients either re-
ceived or did not receive a statement outlining possible
gastrointestinal side effects. This resulted in a sixfold
increase (P < 0.001) in the number of individuals with-
drawing from the study because of subjective, minor
gastrointestinal symptoms [8]. Major (“objective”) com-
plications such as peptic ulcer or bleeding as diagnosed
by study physicians were similar across centers.
There are two gaps in the literature about nocebo ef-
fects within clinical trials. First, the systematic reviews
in the area have not been synthesized. This leaves
questions about the comparative prevalence of AEs
within placebo groups across different conditions un-
answered. Second, the existing systematic reviews often
conflate natural history with nocebo effects. The fact
that an AE occurs after taking a placebo does not
imply that the AE was caused by the placebo. This
mistaken inference was noted in studies investigating
positive placebo effects > 20 years ago [9]. It was
resolved by comparing what happens within three-
armed trials (treatment, placebo, no treatment) to pa-
tients who receive a placebo treatment with patients
who are left untreated. The same method could also
be used to differentiate between nocebo effects and
natural history.
Objectives
In this rapid systematic review, we addressed both of these
gaps and:
(1) synthesized the systematic reviews of nocebo
effects; and
(2) reviewed trials within these systematic reviews that
reported AEs in untreated control groups to
compare these with AEs in placebo groups.
Methods
Protocol and registration
The protocol for this rapid review was published on
PROSPERO on 05/04/18 (record no. CRD42018092437).
Eligibility criteria
We included any systematic review of randomized trials
where AEs were reported and quantified. We included
systematic reviews of trials in any condition. We ex-
cluded reviews of non-randomized trials, and reviews
that did not include quantitative data about AEs within
trial control groups.
Information sources
We searched for PubMed records with the word
“nocebo” in the title and “systematic” in any field (see
Appendix). We also contacted experts and searched ref-
erences of included studies.
Study selection and data collection
Two authors (JH, NK) extracted data from the system-
atic reviews: about year of publication, authors, disease
area, type of AE, and rates of AEs.
Two authors (NK, RW) extracted data from the trials
within the systematic reviews to identify those which in-
cluded AE rates within untreated groups and compared
these with AEs (in the same trial) in placebo groups.
They reported AE rates in all three groups where these
were found. One author (JH) acted as a second extractor
for a random selection (n = 50) of the studies. Discrepan-
cies were resolved by discussion between review authors.
Risk of bias in individual studies
To ensure a minimum level of quality within included
reviews, we assessed whether the following two items of
the Assessment of Multiple Systematic Reviews tool
(AMSTAR) were satisfied: were two or more electronic
sources searched?; and was the scientific quality of the in-
cluded studies assessed and reported? Other overview
authors have used similar assessment criteria [10, 11].
We performed a sensitivity analysis excluding studies
which did not meet the two criteria.
Summary measures
We summarized the median and interquartile ranges
(IQR) of AEs, as reported by review authors, as well as
drop-out rates. When at least three studies reported spe-
cific AEs (such as headache), we reported these, also
using medians and IQRs.
In trials within the reviews that reported AE rates in
untreated groups, we summarized the rates of AEs in
the untreated and placebo groups. To complete this ana-
lysis, we needed references to individual trials within the
reviews. When such references were not published in
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the systematic review, we sent the corresponding author
an email request. If we did not receive a response, we sent
a follow-up email, after which (if we still did not receive a
response) we did not search the trials within that review.
Synthesis of results
We reported the median and IQRs for overall AEs and
dropout rates due to AEs. For our analysis of AEs re-
ported in three or more studies, we also reported me-
dians and IQRs. Among the trials within the review that
included untreated groups, we compared the prevalence
of AEs in untreated groups with the prevalence of AEs
in placebo groups.
Other potential sources of bias
A source of potential bias could have been the method
by which the AEs were ascertained. AE evaluation strat-
egies involving structured assessments (checklists of
likely AEs) risk confusing misattribution of symptoms
caused by the underlying condition to the (placebo)
intervention. For example, pain, nausea, and headaches
are common symptoms of many diseases. Patients who
are asked whether they experienced one of these are
therefore likely to say yes because of the underlying con-
dition or simply because these are common. We could
not infer from the report whether such an event (when
ascertained using structured assessments) was caused by
the underlying condition, a negative expectation, or a
treatment. Spontaneous strategies for measuring AEs ad-
dress this problem by not naming potential AEs in check-
lists and instead asking patients to report any AEs that
arise. We compared AEs assessed using the different
methods in an exploratory analysis. Data were not suitable
for pooling for this analysis so we reported our findings
narratively.
Results
Study selection
Our search yielded 20 systematic reviews (see Fig. 1) that
met our inclusion criteria [12–31]. A total of 1271 ran-
domized trials and 250,726 placebo-treated patients were
included within these reviews.
Study characteristics
The studies were all published in the last 12 years and
pain-related conditions were most commonly studied
Fig. 1 PRISMA diagram records
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within the reviews [12–14, 16, 19, 20, 23]. Other condi-
tions were: depression [18, 21, 24, 26]; multiple sclerosis
[22]; motor neuron disease [27]; restless leg syndrome
[28]; Parkinson’s disease [29]; Alzheimer’s [30]; cardio-
vascular disease [25]; and epilepsy [31]. Two reviews in-
cluded trials in any condition [15, 17].
Some of the reviews reported data separately for
different types of treatments or conditions without
combining the data. Amanzio et al. [12] reported trials of
non-steroidal, anti-inflammatory drugs (NSAIDs); trip-
tans, and anticonvulsants separately; Häuser et al. [13]
reported data for fibromyalgia and painful diabetic
neuropathy trials separately; Mitsikostas et al. [19] re-
ported data for symptomatic and prophylactic trials separ-
ately. Papadopoulos et al. [22] reported symptomatic and
disease-modifying trials separately, and Rief et al. [25]
reported tricyclic (TCA) and selective serotonin reuptake
inhibitor (SSRI) trials separately. We followed the authors
and did not combine the separately reported data.
Ninety distinct types of AEs were reported. These ranged
from abdominal pain and dry mouth to cancer and stroke.
Risk of bias within studies
Eight reviews [12, 13, 15, 16, 18, 25, 26, 28] met both of
our quality criteria (searched at least two databases and
reported data about quality of included trials, see Add-
itional file 1: Table S1). Seven reviews met neither quality
criteria [19, 20, 22–24, 27, 30]. Of the five studies that met
one of our quality criteria, one [14] searched more than
one database and four assessed and reported the quality of
included studies [17, 21, 29, 31]. There were insufficient
data to formally analyze the relationship between review
quality and AE data; however, there did not seem to be
any correlation between review quality and AEs. Studies
which met at least one criteria had the highest rates of
AEs (64.7%) compared with studies that met both criteria
(36.6)%) and no criteria (54.9%), while the rates of drop
out were similar across those which met no (6%), one
(4.8%), and both (5.3%) quality criteria.
Results of individual studies and synthesis of results
The results of individual studies are provided in Table 1.
The median prevalence of AEs in trial placebo groups
(as defined by the individual trials within the reviews)
was 49.1% (IQR 25.7–64.4%). The median rate of drop-
outs due to AEs was 5% (IQR 2.28–8.4%).
Only some reviews provided details about specific AEs
reported within the reviewed trials. In all, 90 different AEs
were reported and 17 types of AEs were reported in at
least three trials (see Table 2). Eight of these had median
rates > 5%: headache (18%); vomiting (7.7%); fatigue
(7.11%); insomnia (5.7%); burning (5.88%); somnolescence
(5.56%); dizziness (5.1%); and constipation (6.43%).
Fifteen trials within the reviews contained data about
AEs reported in untreated groups (see Table 3). The
average AE rate in these trials was smaller than the AE
rate in placebo groups and treatment groups within the
same trials (4.25%, 6.51%, and 5.93%, respectively). The
AE rate in the placebo groups was higher than that of
the untreated groups, although the difference was not
statistically significant (P = 0.07), tentatively suggesting
that the AE rates cannot be attributed to natural history.
One study reported AEs within untreated groups, but
not in a format we could pool [32]. In it, the authors
found no significant differences between AEs reported in
untreated, placebo, or treatment groups.
Other sources of bias
Structured assessment seemed to result in different AE
reports in some of the reviews (see “Additional analyses”).
Additional analyses
Two reviews checked for differences between included
trials with high versus low quality [12, 29]. Amanzio et
al. [12] found that of 28 types of AEs measured, only
one (somnolescence) showed a difference. Stathis et al.
[29] found that the higher the trial quality (measured by
Jadad scores), the lower the dropout rate in placebo
groups.
Four reviews reported data about structured versus
spontaneous reports of AEs [12, 14, 25, 26]. Only one of
these found a statistically significant difference between
AEs reported by different methods: Rief et al. [25] found
it to be more than twice as likely for an AE to be re-
ported using structured as opposed to spontaneous as-
sessment methods (odds ratio 2.6, 95% confidence
interval 2.1–3.3). For the 24 types of AEs where it was
possible to compare spontaneous versus structured as-
sessment, Amanzio et al. [12] did not find statistically
different rates of AE reporting in 21 of them. Among
the AEs where there was a difference, structured assess-
ments resulted in higher prevalence of AEs for nausea in
NSAID trials; spontaneous assessment resulted in
greater AEs for fatigue in NSAID trials and nausea in
Triptans trials. Hauser et al. [14] planned to compare
AE rates for different assessment strategies but decided
post hoc not to, due to poor quality of reports of assess-
ment strategies; there did not appear to be a difference.
Rojas-Mirquez et al. [26] reported which trials used dif-
ferent assessment methods but did not say whether
there was a difference (and none were obvious by visual
inspection).
Discussion
Summary
Our overview of systematic reviews of nocebo effects
suggests that almost half of patients in the placebo
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groups within clinical trials experience AEs that are at-
tributed to the drug. One in 20 patients in placebo
groups drop out due to drug intolerance. This is higher
than similar reports of AEs reported by patients taking the
same interventions in routine clinical practice [14, 25].
Comparison with other evidence
Our study adds to the existing reviews showing that AEs
are common among patients in placebo groups within
clinical trials. We showed that this phenomenon is
common across several conditions and extends to many
types of AEs. We also added a comparison of AEs in un-
treated groups, which suggested that natural history or
misattribution is unlikely to explain the AEs reported
within the placebo groups.
Strengths and limitations
This is the first synthesis of AEs that covers both different
disease areas and different types of placebos. It is also the
first to investigate natural history as a potential cause of
AEs within trial placebo groups. Our conclusions are
Table 1 Summary of adverse effects in placebo groups within trials
Author Disease Trials (no patients
in placebo group)
Adverse
events (%)
Dropouts due to
intolerance (%)
Amanzio, 2009 Migraine
NSAID placebos 10 (337) 4.16 1.00
Triptans placebos 3 (289) 2.08 0.39
Anticonvulsant placebos 6 (142) 5.57 7.71
Häuser, 2012a Fibromyalgia 58 (5027) 59.90 9.60
Painful diabetic peripheral neuropathy 62 (5086) 46.20 5.80
Häuser, 2012b Fibromyalgia syndrome 18 (3546) 10.90
Koog, 2014a Any treated by acupuncture 58 (2249) 13 1.36
Koog, 2014b Knee osteoarthritis 281 (22,284) 27 4.80
Mahr, 2017 Any 231 (149,855) 73 5.10
Mahr, 2017 (additional)
Meister, 2017 Depression 23 (2929) 57.00 4.00
Mitsikostas, 2010 Headaches 56 (n/a)
Symptomatic treatments n/a (n/a) 18.45 0.33
Prophylactic treatments n/a (n/a) 42.78 4.75
Mitsikostas, 2012 Fibromyalgia 16 (2016) 67.20 9.50
Mitsikostas, 2014 Depression 21 (3255) 44.70 4.50
Papadopoulos, 2010 Multiple sclerosis
Symptomatic treatments 44 (1732) 25.30 2.10
Disease-modifying treatments 56 (5623) 74.42 2.34
Papadopoulos, 2012 Neuropathic pain 12 (943) 52 6.00
Rief, 2006 Cardiovascular disease 17.61
Rief, 2009 Depression or anxiety 143 (12,742) 24.70
TCA studies
SSRI studies
Rojas-Mirquez, 2014 Depression 16 (739) 64%
Shafiq, 2017 Motor neuron disease 12 (1288) 78.30 8.40
Silva, 2017 Restless leg syndrome 72 (5040) 45.36 2.07
Stathis, 2013 Parkinson’s disease 41 (3544) 64.70 8.80
Zis, 2015 Alzheimer’s disease 20 (3049) 57.80 6.60
Zis, 2017 Refractory partial epilepsy
(during pre-surgical monitoring)
4 (125) 76.80 3.20
Median (IQR) 49.1% (25.8–64.5%) 5% (2.3–8.4%)
FMS fibromyalgia syndrome, DPN diabetic peripheral neuropathy
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Table 2 Adverse event (AE; %) within placebo groups, by type of AE (where at least three reviews reported the same AE)
Amanzio, 2009 Mahr, 2017a Mahr, 2017b Rief, 2006 Rief, 2009 Rojas-Mirquez, 2014 Median (IQR)
Aa Bb Cc TCA SSRI
Abdominal pain 2.97 1.04 1.04 6.8 3.3 8.4 9 5.68 4.5 (2.5–7.2)
Burning 5.88 1.83 8.7 5.9 (3.9–7.3)
Chest discomfort/pain 0 0.8 4.2 0.82 0.8 (0.6–1.7)
Chills 1.4 0.47 3.7 1.4 (0.9–2.6)
Diarrhea 1.25 3.51 7.7 3.53 3.5 (2.9–4.6)
Dry mouth 4.26 1.75 3.11 5.1 19.2 6.4 4.7 (3.4–6.1)
Dyspepsia 1.13 1.46 3.21 3.9 2.03 2.0 (1.5–3.2)
Fatigue 2.85 1.47 8.72 9.3 17.3 5.5 7.1 (3.5–9.2)
Insomnia 0 5.7 13.3 11.1 4.73 5.7 (4.7–11.1)
Paresthesia 1.1 0.88 6.58 3.6 2.4 (1.0–4.3)
Somnolence 1.05 2.76 5.67 16.8 6.8 5.44 5.6 (3.4–6.5)
Taste disturbance 1.06 1.34 4.1 1.3 (1.2–2.7)
Vomiting/nausea 8.9 4.38 2.11 7.7 4.9 2.55 12 10.5 8.18 7.7 (4.4–8.9)
Headache 9.9 10.59 27.4 19.9 18.01 18.0 (10.6–19.9)
Dizziness 5.1 1.81 5.5 5.1 (3.5–5.3)
Eye disorders 1.4 6.9 1.2 1.4 (1.3–4.2)
Constipation 6 6.85 10.7 4.2 6.4 (5.6–7.8)
aNSAID
bTriptans
cAnti-convulsant
Table 3 Adverse events (AE) in placebo groups compared with AEs in untreated groups
Study Review in
which study
is contained
Patients reporting AEs (n)
No treatment Placebo group Treatment group
n N n N N N
Barrett, 2010 Mahr, 2017 18 174 23 179 29 184
Bokmand, 2013 Koog, 2014a 1 34 8 29 5 31
Vas, 2012 Koog, 2014a 6 70 5 137 1 68
Choi, 2010 Koog, 2014a 1 14 2 15 2 15
Lee, 2009 Koog, 2014a 0 12 1 12 0 12
Sertel, 2009 Koog, 2014a 0 41 0 41 0 41
Friere, 2007 Koog, 2014a 0 12 0 12 0 12
Gioia, 2006 Koog, 2014a 0 25 0 25 0 25
Cabrini, 2006 Koog, 2014a 0 16 0 16 0 16
Melchart, 2005 Koog, 2014a 1 75 0 63 2 132
Linde, 2005 Koog, 2014a 2 76 1 81 4 145
Molsberger, 2002 Koog, 2014a 0 60 0 61 0 65
Leibing, 2002 Koog, 2014a 0 40 0 45 3 40
Medici, 2002 Koog, 2014a 0 20 0 23 2 23
Ma, 2010 Koog, 2014a 0 13 0 12 0 27
Total 29 682 40 614 48 809
Percentage 4.25% 6.51% 5.93%
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limited by the quality of the included systematic reviews
and the quality of the trials within the systematic reviews.
This limitation is mitigated by our quality assessment of
the included systematic reviews, which suggests that they
meet a minimum quality standard. Another limitation is
that a second extractor only reviewed a random selection
of studies independently. This is unlikely to have had an
important influence on the results as there were only five
discrepancies, mostly about the nature of follow-up in un-
treated groups within individual trials.
It was also difficult to disentangle different possible
causes of AEs within placebo groups. While our analysis
did not reveal any clear trend in AE reports by ascertain-
ment method (structured versus spontaneous), it re-
mains possible that the way patients are asked to report
AEs could influence what they report. This compounds
the problem of distinguishing between effects of negative
expectations and the effects of mistakenly attributing
routine symptoms to a trial intervention. Hence, future
experimental studies where expectations are manipu-
lated are likely to be required to determine the potency
of negative expectations. Relatedly, the included reviews
did not define AEs, perhaps due to the failure of the in-
cluded trials to do so.
Implications for clinical trials and clinical practice
There are three implications of this study for trial method-
ology. First, methods to reduce the risk of AEs induced by
negative expectations (that may arise due to the way pos-
sible harms are communicated) warrant investigation [33].
Some studies have already begun to address how clinicians
might reduce nocebo effects within clinical trials, such as
limiting suggestion of symptoms [34]. Identifying a model
of informed consent that respects patient autonomy yet
does not introduce unnecessary harm is therefore re-
quired. This might be achieved by shortening the in-
formed consent process so that rare harms are made clear
(for example, by being listed on a web page for patients
who would like to know) but not forced upon patients.
Oxman et al. proposed such a model [35], but it has not
yet been implemented. Other ethicists have also called for
“contextualizing” informed consent (adapting it for indi-
vidual patients) [36]. Contextualized consent may enable
practitioners to present benefits and harms to patients in
ways that do not induce unnecessary nocebo effects. Sec-
ond, we should modify the way AEs are collected such
that natural history is not confused with AEs. This might
be achievable with a combination of spontaneous and
structured AE assessments.
Third, the inferences about intervention AEs needs to
be rethought. This is typically calculated by comparing
AE rates in treatment groups with AE rates in placebo
groups. But if the AE rates in placebo groups are inflated
by the way potential AEs are communicated to patients,
this can lead to an overestimation of AEs in placebo
groups and a consequent underestimation of AEs attrib-
uted to experimental treatments. The way AEs in trials
are interpreted should therefore reflect the findings from
this review.
Finally, our review also raises the ethical issue of bal-
ancing the need to respect patient autonomy and pro-
vide full informed consent, while at the same time
reducing unnecessary harm done to patients. The former
seems to demand that more information about AEs is
provided, while the latter suggests that such information
should be carefully communicated to avoid harms.
Conclusions
Trial participants who receive placebos within clinical
trials report experiencing AEs. Research on clinical trial
methodology is now warranted to reduce this potentially
unnecessary harm.
Appendix
PubMed search strategy
Search date: 22 November 2017
nocebo[TI] AND Review[ptyp]
Additional file
Additional file 1: Table S1. Review quality according to selected
AMSTAR criteria. (DOCX 21 kb)
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